Triglimibrit 2mg/500mg/0.3mg Tablet SR
Marketer
Elbrit Life Sciences
Salt Composition
Glimepiride (2mg) + Metformin (500mg) + Voglibose (0.3mg)
Overview Triglimibrit 2mg/500mg/0.3mg Tablet SR
DiabexTrio 2mg/500mg/0.3mg Extended-Release Tablets are classified as antidiabetic agents. This combination medication manages type 2 diabetes in adults by regulating blood glucose. DiabexTrio 2mg/500mg/0.3mg Extended-Release Tablets should be administered with food, consistently at the same time daily for optimal efficacy. Dosage is determined and adjusted by your physician based on your blood sugar response. Continued use is crucial, even with well-controlled blood sugar, as discontinuation without medical supervision can lead to elevated glucose levels, risking kidney complications, vision impairment, neuropathy, and limb loss. This medication complements a comprehensive diabetes management plan encompassing a healthy diet, regular physical activity, and weight management as directed by your doctor. Lifestyle modifications significantly impact diabetes control. Hypoglycemia (low blood sugar) is a prevalent side effect, manifesting as sweating, dizziness, headache, and tremors. Prompt glucose intake (e.g., sugary foods, fruit juice) is essential. Alcohol consumption should be minimized due to its hypoglycemic potential. Additional potential side effects include altered taste, nausea, diarrhea, abdominal discomfort, headache, edema, blurred vision, bone fractures, and upper respiratory infections. Weight gain may occur. This medication is contraindicated in type 1 diabetes, diabetic ketoacidosis, and severe hepatic or renal impairment. Prior heart conditions should be disclosed to your physician before commencing treatment. Pregnant or lactating individuals require medical consultation before use. Regular blood glucose monitoring and periodic blood tests (blood cell counts, liver function) are recommended.
Primary Ingredients of Triglimibrit 2mg/500mg/0.3mg Tablet SR
The provided text is "undefined," which lacks meaning and cannot be rephrased. A meaningful text is required for a paraphrase.
Uses of Triglimibrit 2mg/500mg/0.3mg Tablet SR
Managing type 2 diabetes
Major Benefits of Triglimibrit 2mg/500mg/0.3mg Tablet SR:
Administer this medication precisely as prescribed by your physician, adhering to both the dosage and treatment length. Ingest the entire tablet without chewing, crushing, or fracturing it. Consume Triglimibrit 2mg/500mg/0.3mg Extended-Release Tablets on an empty stomach.
Common Side effects of Triglimibrit 2mg/500mg/0.3mg Tablet SR:
- Nausea
- Diarrhea
- Abdominal pain
- Hypoglycemia (low blood glucose level)
- Loss of appetite
How to use Triglimibrit 2mg/500mg/0.3mg Tablet SR:
Administer this medication precisely as your physician directs, adhering to the prescribed dosage and treatment period. Ingest the Triglimibrit 2mg/500mg/0.3mg Tablet SR whole; avoid chewing, crushing, or breaking it. Consume this extended-release tablet on an empty stomach.
How Triglimibrit 2mg/500mg/0.3mg Tablet SR works:
Extended-release Triglimibrit tablets (2mg/500mg/0.3mg) contain a triple combination of antidiabetic agents.
SAFETY ADVICE
AlcoholUNSAFE
Combining Triglimibrit 2mg/500mg/0.3mg SR tablets with alcohol is inadvisable.
PregnancyCONSULT YOUR DOCTOR
Extended-release Triglimibrit tablets (2mg/500mg/0.3mg) might pose risks during pregnancy. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the advantages against potential hazards prior to prescription. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
The extended-release Triglimibrit 2mg/500mg/0.3mg tablet is likely unsafe for breastfeeding mothers. Available human data indicates potential transfer to breast milk, posing a risk to the infant.
DrivingCAUTION
Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these blood sugar imbalances.
KidneyUNSAFE
Employing Triglimibrit 2mg/500mg/0.3mg SR tablets is likely inadvisable for individuals with kidney impairment and should be forgone. A physician's consultation is recommended. Furthermore, the use of Triglimibrit 2mg/500mg/0.3mg SR tablets is discouraged in those experiencing severe kidney dysfunction.
LiverCAUTION
Patients with liver impairment should use Triglimibrit 2mg/500mg/0.3mg SR tablets cautiously, as dose modification may be necessary. Individuals with severe liver disease should avoid this medication. For those with mild to moderate liver disease, a low initial dose is typically prescribed. Physician consultation is recommended.
What if you forget to take Triglimibrit 2mg/500mg/0.3mg Tablet SR :
Should you forget to take your Triglimibrit 2mg/500mg/0.3mg Tablet SR, administer it immediately upon recollection. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Triglimibrit 2mg/500mg/0.3mg Tablet SR
| Label | Value |
|---|---|
| Developing Habits | No. |
| Type of Therapy | Diabetes Management |
3,018 People bought this recently